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1. INTRODUCTION 2. MATERIALS AND METHODS 
Addition of the divalent cation ionophore, 
A23187, to suspensions of human peripheral blood 
PMN leads to the formation of LTB4 [1] which is 
synthesized from arachidonic acid via the lipoxy- 
genase product, 5-HPETE and an unstable epox- 
ide intermediate, leukotriene A4 [2-5]. LTB4, un- 
like 5-HETE and 12-HETE, is not incorporated 
into cellular phospholipids and triglycerides [6,7]; 
however, it is metabolized by ~0-oxidation to 20-hy- 
droxy-LTB4 and 20-carboxy-LTB4 [8]. We have 
monitored the synthesis of LTB4 in human PMN 
stimulated with A23187 with or without exogenous 
arachidonic acid, using the RIA for LTB4 in [9]. 
Also, we have investigated the metabolism of 
LTB4 in human PMN using RIA and radiochemi- 
cal techniques. 
Abbreviations: leukotriene B4 (LTB4), 5(S),12(R)-dihy- 
droxy-6,14-cis-8,10-trans-eicosatetraenoic acid; 5-HPETE, 
5(S)-hydroperoxy-6,8,11,14-eicosatetraenoic acid; leu- 
kotriene A4, 5,6-epoxy-7,9,11,13-eicosatetraenoic acid; 
5-HETE, 5(S)-hydroxy-6,8,11,14-eicosatetraenoic acid; 
12-HETE, 12(S)-hydroxy-5,8,10,14-eieosatetraenoic acid; 
PMN, polymorphonuclear leukocytes; PG, prostaglan- 
din; TX, thromboxane; RIA, radioimmunoassay; RP- 
HPLC, reverse phase-high pressure liquid chromatog- 
raphy; SP-HPLC, straight phase-high pressure liquid 
chromatography 
LTB4 was obtained from Professor E.J. Corey, 
Harvard University (Cambridge MA). Arach- 
idonic acid (99% pure) and A23187 were pur- 
chased from Sigma Chemicals (St Louis MO) and 
Calbiochem (La Jolla CA), respectively. [3H]LTB4 
was biosynthesized from [3H]arachidonic acid 
(Amersham International, Amersham, Bucks) and 
purified as in [9]; subsequent batches of [3H]LTB4 
(30 Ci/mmol) were a generous gift of Dr D. 
Copsey, Amersham International. Analytical grade 
and HPLC grade solvents were purchased from 
BDH (Poole, Dorset) and Rathburn Chemicals 
Ltd. (Walkerburn, Peebleshire), respectively. 
2.1. Biosynthesis of LTB4 
PMN were obtained from peripheral blood of 
healthy volunteers as in [10]. These cells (5 x 106 
cells in ! ml Hepes-buffered Hank's balanced salt 
solution, pH 7.4) were incubated at 37°C in dupli- 
cate with A23187 (0.01-1.0/zg/ml) and/or arach- 
idonic acid (10 p.g/ml). The incubation was termi- 
nated by centrifugation at 12 000 × g for 30 s. The 
concentrations of LTB4, PGE2 and TXB2 in the 
cell-free supernatant were determined by specific 
RIA [9,11] after suitable dilution in RIA buffer. 
2.2. Metabolism of LTB4 
LTB4 (final conc. 20 ng/ml) was incubated with 
suspensions of human PMN (5 x 106 cells/ml) at 
37°C for 2-90 min. After centrifugation, superna- 
tant LTB4 was measured by RIA. The effect of 
human PMN on TXB2 and PGE 2 was similarly 
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monitored by specific RIA after addition of each 
compound (final conc. 5 ng/ml) to 5 × 106 cells. 
2.3. Metabolism of[3H]LTB4 
[3H]LTB4 (30 nCi; 0.504 Ci/mmol) was added 
in ethanol (4/~1) to a 1 ml suspension of 5 × 106 
cells and incubated at 37°C for 1-90 min. Cells 
were removed by centrifugation and the radioac- 
tivity present in an aliquot of supernatant (50 ~tl) 
and in the cell pellet was determined by con- 
ventional liquid scintillation techniques. After ad- 
dition of PGB2 (500 ng), the remainder of the su- 
pernatant was extracted and subjected to silicic 
acid chromatography as in [9]. The ethyl acetate 
fraction from silicic acid chromatography was 
evaporated to dryness under vacuum and the resi- 
due dissolved in HPLC solvent (methanol - water 
- acetic acid; 69:31:0.02, by vol.). This solution 
was injected onto a Zorbax C-8 column (Dupont 
Instruments, Wilmington DE) and eluted with 
HPLC solvent at 1 ml/min using a Waters Associ- 
ates (Northwich, Cheshire) Model 6000A solvent 
delivery system. Fractions (1 ml) were collected, 
evaporated to dryness under nitrogen and then re- 
dissolved in RIA buffer. Immunoreactive LTB4 in 
each fraction was measured by RIA [9]. Also, the 
radioactivity in an aliquot was determined by 
liquid scintillation counting. These data were cor- 
rected for procedural losses as estimated by the re- 
covery of PGB2. 
3. RESULTS 
The divalent cation ionophore, A23187, stimu- 
lated the synthesis of immunoreactive LTB4 from 
human PMN (fig.l); this material has been con- 
firmed to be LTB4 by RP-HPLC following extrac- 
tion and silicic acid chromatography [9]. Low but 
variable concentrations of LTB4 were detected 
after addition of arachidonic acid alone; however, 
release was markedly stimulated by simultaneous 
addition of arachidonic acid and A23187 (fig.l). 
On the other hand, the concentrations of TXB2 
(and PGE2, not shown) measured after incubation 
with arachidonic acid were not increased further 
by addition of A23187. 
Peak concentrations of LTB4 were detected 5 -  
10 min after A23187 addition and thereafter the 
level declined (fig.l). [LTB4] decreased similarly 
after addition of exogenous LTB4 (20 ng) to 
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Fig.l. Time course of the effect of A23187, with and 
without arachidonic acid, on LTB4 and TXB 2 synthesis 
by human PMN: A23187, 0.1 /~g/ml (-0-); arachidonic 
acid, 10 /~g/ml (-e-); A23187, 0.1 ~g/ml, plus arach- 
idonic acid, 10 ~g/ml (-~-). Each point is the mean of 
duplicates. 
5 × 106 human PMN (fig.2). The loss of immu- 
noreactive material appeared to occur by a first- 
order process with a half-life of 25 min at 37°C. 
The half-life was extended to 1 h if incubation was 
performed at 21 °C. No significant loss of LTB4 oc- 
curred when it was incubated for 90 min in the ab- 
sence of cells (fig.2). The concentrations of neither 
PGE 2 nor TXB2 decreased uring 60-90 min in- 
cubation with human PMN at 37°C. 
On addition of [3H]LTB4 to human PMN, there 
was initial association of label with the cells as in- 
dicated by increased radioactivity in the cell pellet 
which was parallelled by decreased radioactivity in
the cell-free supernatant (fig.3). Maximum levels 
of cell-associated radioactivity occurred between 
19 
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Fig.2. Decay of eicosanoids in the presence of human PMN. LTB4 (20 ng), PGE 2 (5 ng) or TXB 2 (5 ng) were incubated 
with 5 x 106 cells in 1 ml medium at 37°C or 21 °C as indicated. Data, presented as % of the concentration atzero time, 
are the mean _+ SEM (n = 4) or the mean of duplicates. 
5-15 min, after which there was a slow loss of la- 
bel from the cell pellet to the supernatant. Follow- 
ing extraction and silicic acid chromatography, 
RP-HPLC of supernatants from incubations of 
cells with [3H]LTB4 revealed two separate peaks of 
radioactivity (rigA). One peak (II) had an identical 
elution time to that of authentic LTB4 (23 min) 
while the other peak (I) eluted at 7 min. The 
amount of radioactivity co-eluting with LTB4 pro- 
gressively decreased as the incubation time of 
[3H]LTB4 with human PMN increased; -50% la- 
bel eluted in peak II after 30 min incubation and 
was almost undetectable after 90 min. The de- 
crease in radioactivity co-eluting with LTB4 was 
almost precisely paralleled by an increase in radio- 
activity eluting in peak I. Radioimmunoassay of 
the RP-HPLC fractions revealed immunoreactivity 
only at the elution time of authentic LTB4 (rigA); 
the partial separation of unlabelled (immunoreac- 
tire) and radioactive compound by HPLC which 
we observed has also been reported for other com- 
pounds [12]. The amount of immunoreactive LTB4 
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Fig.3. Time course for the uptake and decay of 
[3H]LTB 4 in human PMN. [3H]LTB4 (30 nCi; 20 ng) 
was incubated with cells (5 x 106) at 37°C. Total radio- 
activity in the supernatant (-=-) and cell pellet (-[]-) 
were determined by conventional liquid scintillation 
techniques. [3H]LTB 4 (-o--) and immunoreactive LTB4 
(--e-) were determined after RP-HPLC (see rigA). Ra- 
dioactivity in the supernatant, immunoreactive LTB4 
and [3H]LTB4 are expressed as % of zero-time levels. 
Radioactivity in the cell pellet is presented as the per- 
centage of that in the supernatant at zero time. Each 
point is the mean of duplicate determinations. 
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Fig.4. Determination f radioactivity and immunoreac- 
tivity following RP-HPLC of [3H]LTB4 incubated with 
human PMN. Cells (5 × 106/ml) were incubated with 
20 ng [3H]LTB4 (30 nCi) for: (A) 1 min; (B) 30 min; (C) 
90 min. The cell-free supernatant was extracted and pu- 
rified by silicic acid chromatography prior to RP-HPLC 
as in section 2. The amounts of radioactivity (-e-) and 
immunoreactivity (~-) in the eluate were determined 
by liquid scintillation counting and RIA, respectively. 
The data were corrected for procedural losses estimated 
by the recovery of PGB 2 which was eluted as shown 
(. . .) .  
decreased with time of incubation and correlated 
with the loss of [3H]LTB4 (fig.3,4). The LTB4 me- 
tabolite eluting at 7 min was not associated with 
immunoreactivity even after 90 min incubation at 
which time almost all the added LTB4 (20 ng) had 
been transformed. 
4. DISCUSSION 
Using a specific RIA for LTB 4 we have con- 
firmed the observations [1] that LTB4 synthesis by 
human PMN is stimulated by A23187. However, 
A23187 did not significantly induce release of 
cyclo-oxygenase products (TXB2 and PGE2), thus 
demonstrating specific 'activation' of the enzyme 
system involved in the synthesis of LTB4. Synthesis 
of LTB4 was potentiated by simultaneous addition 
of exogenous arachidonic acid particularly at short 
incubation times (1-2 min). This suggests that the 
enzyme system for converting arachidonic acid 
into LTB4 is rapidly 'activated' upon addition of 
A23187. The lag-time observed before maximum 
LTB4 synthesis from endogenous substrate proba- 
bly reflects the time required for A23187 to stimu- 
late the phospholipase-dependent release of arach- 
idonic acid from phospholipids. A high rate of 
LTB4 synthesis could be maintained by further ad- 
ditions of arachidonic acid (not shown). This indi- 
cates that the enzymes involved in the synthesis of 
LTB4 from arachidonic acid remain active longer 
than suggested by the time for maximum synthesis 
of LTB4 (5-10 min). Therefore, the decreased pro- 
duction of LTB4 after 10 min challenge with 
A23187 probably reflects limited substrate avail- 
ability. 
The fall in [LTB4] occurring 5-10 min after 
A23187 stimulation was similar to the decline ob- 
served after addition of exogenous LTB4. The loss 
of LTB4 does not occur in the absence of cells and 
is more rapid at 37°C than at 21°C and therefore 
probably reflects an enzymic transformation. Nei- 
ther PGE2 nor TXB2 exhibit a similar decrease in 
concentration when added to human PMN which 
offers an explanation for the different ime-course 
profiles between LTB4 and the cyclo-oxygenase 
products after A23187 stimulation. LTB4, PGE 2 
and TXB2 all reach peak concentration within 5-  
10 min but, whereas the concentration f LTB4 de- 
clined to 10% maximum after 90 min, the levels of 
TXB2 and PGE 2 remained constant. 
The mechanism for the decline in [LTB4] in 
human PMN was more carefully probed using ra- 
diochemical procedures. There was initial associa- 
tion of label with cells upon addition of [3H]LTB4 
but this was followed by dissociation after 15 min. 
The explanation for this data was provided, after 
extraction and silicic acid chromatography, b  RP- 
HPLC of [3H]LTB4 incubated with human PMN. 
Initially all the radioactivity co-eluted with LTB4 
but at longer times of incubation a more polar 
compound was detected. This metabolite did not 
crossreact in the RIA for LTB4. Human PMN me- 
tabolize LTB4 to 20-hydroxy-LTB4 and 20-car- 
boxy-LTB4 [8]. The metabolite observed here is 
probably one of these compounds: its elution time 
in RP-HPLC and SP-HPLC systems (the latter as 
the methyl ester) suggest that it is 20-hydroxy- 
21 
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LTB4 (not shown). Thus, exogenous LTB4 is taken 
up by PMN, metabolized, and then the metabolite 
(probably 20-hydroxy-LTB4) is released. 
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